At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
AN2728 ointment, 2% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating AN2728 ointment, 2%, AN2898 ointment, 1%, and 2 other interventions for Dermatitis, Atopic. Completed, enrolled 46 participants across 13 sites.
Detailed Summary
The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedFeb 23, 2011
Enrollment StartMay 1, 2011
Primary CompletionNov 11, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.4 years ago
Interventions
AN2728 ointment, 2%drug
AN2728 ointment, 2%, applied twice daily for 6 weeks
AN2898 ointment, 1%drug
AN2898 ointment, 1%, applied twice daily for 6 weeks
AN2898 ointment vehicledrug
AN2898 ointment vehicle applied twice daily for 6 weeks
AN2728 ointment vehicledrug
AN2728 ointment vehicle applied twice daily for 6 weeks